Medication for Opioid Use Disorder (MOUD) has been shown to be a safe, cost-effective intervention that successfully lowers risk of opioid overdose. However, access to and use of MOUD has been limited. Our objective was to explore attitudes, opinions, and beliefs regarding MOUD among healthcare and social service providers in a community highly impacted by the opioid overdose epidemic.
Methods
As part of a larger ethnographic study examining neighborhoods in Allegheny County, PA, with the highest opioid overdose death rates, semi-structured qualitative in-person and telephone interviews were conducted with forty-five providers treating persons with opioid use disorders in these communities. An open coding approach was used to code interview transcripts followed by thematic analysis.
Results
Three major themes were identified related to MOUD from the perspectives of our provider participants. Within a variety of health and substance use service roles and settings, provider reflections revealed: (1) different opinions about MOUD as a transition to abstinence or as a long-term treatment; (2) perceived lack of uniformity and dissemination of accurate information of MOUD care, permitting differences in care, and (3) observed barriers to entry and navigation of MOUD, including referrals as a “word-of-mouth insider system” and challenges of getting patients MOUD services when they need it.
Conclusions
Even in communities hard hit by the opioid overdose epidemic, healthcare providers’ disagreement about the standard of care for MOUD can be a relevant obstacle. These insights can inform efforts to improve MOUD treatment and access for people with opioid use disorders.
LarochelleMR, StopkaTJ, XuanZ, LiebschutzJM, WalleyAY.Medication for opioid use disorder after nonfatal opioid overdose and mortality. Ann Intern Med. 2019;170(6):430–431.
3.
MattickRP, BreenC, DavoliKJ.M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;23(2):CD002207.
4.
SchuckitMA.Treatment of opioid-use disorders. N Engl J Med. 2016;375(16):1596–1597.
5.
KrupitskyE, NunesEV, LingW, IlleperumaA, GastfriendDR, SilvermanBL.Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513.
6.
JarvisBP, HoltynAF, SubramaniamSExtended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction. 2018;113(7):1188–1209.
7.
WilliamsAR, NunesEV, BisagaADeveloping an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57–68.
8.
BlancoC, VolkowND.Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–1772.
9.
RosenblattRA, AndrillaCH, CatlinM, LarsonEH.Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.
10.
MojtabaiR, MauroC, WallMM, BarryCL, OlfsonM.Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff. 2019;38(1):14–23.
11.
FinlayAK, MorseE, StimmelMBarriers to medications for opioid use disorder among veterans involved in the legal system: a qualitative study. J Gen Intern Med. 2020;35(9):2529–2536.
12.
RawsonRA, RieckmannT, CousinsS, McCannM, PearceR.Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. Prev Med. 2019;128:105785.
13.
JacobsonN, HorstJ, Wilcox-WarrenLOrganizational facilitators and barriers to medication for opioid use disorder capacity expansion and use. J Behav Health Serv Res. 2020;47(4):439–448.
14.
LouieDL, AssefaMT, McGovernMP.Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.
15.
LivingstonJD, AdamsE, JordanM, MacMillanZ, HeringR.Primary care physicians’ views about prescribing methadone to treat opioid use disorder. Subst Use Misuse. 2018;53(2):344–353.
16.
VogelM, NordtC, DurstelerKMEvaluation of medication-assisted treatment of opioid dependence-the physicians’ perspective. Drug Alcohol Depend. 2016;164:106–112.
17.
SpencerNE, TaubenbergerSP, RobertoR, KrishnamurtiLS, ChangJC, HackerK. “Stories of starting”: Understanding the complex contexts of opioid misuse initiation. Subst Abus. 2021:1–16. doi:10.1080/08897077.2021.1878084
18.
TaubenbergerS, SpencerN, ChangJCA rapid-cycle assessment strategy for understanding the opioid overdose epidemic in local communities. Subst Abus. 2021:1–15. doi:10.1080/08897077.2021.1891601
FitchC, StimsonGV, RhodesT, PoznyakV.Rapid assessment: an international review of diffusion, practice and outcomes in the substance use field. Soc Sci Med. 2004;59(9):1819–1830.
23.
StimsonGV, FitchC, DesJarlaisDRapid assessment and response studies of injection drug use: knowledge gain, capacity building, and intervention development in a multisite study. Am J Public Health. 2006;96(2):288–295.
24.
PattonMQ.Qualitative research evaluation methods.3rd ed. Thousand Oaks, CA: Sage; 2002.
25.
ThomasDR.A general inductive approach for analyzing qualitative evaluation data. American Journal of Evaluation. 2006;27(2):237–246.
26.
GlaserBG.Open coding descriptions. Grounded Theory Review. 2016;15(2):108–110.
27.
CascioMA, LeeE, VaudrinN, FreedmanDA.A team-based approach to open coding: considerations for creating intercoder consensus. Field Methods. 2019;31(2):116–130.
28.
VaismoradiM, TurunenH, BondasT.Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398–405.
29.
BraunV, ClarkeV.Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101.
30.
SellsSB.Methadone maintenance in perspective. Journal of Drug Issues. 1977;7(1):13–22.
31.
Kennedy-HendricksA, BarryCL, GollustSE, EnsmingerME, ChisolmMS, McGintyEE.Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017;68(5):462–469.
32.
ZwebenJE, PayteJT.Methadone maintenance in the treatment of opioid dependence. A current perspective. West J Med. 1990;152(5):588–599.
33.
VolkowND, FriedenTR, HydePS, ChaSS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
34.
HuntDE, LiptonDS, GoldsmithDS, StrugDL, SpuntB. “It takes your heart”: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict. 1985;20(11–12):1751–1771.
SorrellTR, WeberM, AlvarezAFrom policy to practice: pilot program increases access to medication for opioid use disorder in rural Colorado. J Subst Abuse Treat. 2020;114:108027.
LevinFR, BisagaA, SullivanMA, WilliamsAR, Cates-WesselK.A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25(8):603–609.
43.
MeyersT.Things under the tongue: pharmacotherapy, its intersections and its afterlife in urban America. The Johns Hopkins University. Proquest Dissertations Publishing; 2009.
44.
WeinsteinZM, GryczynskiG, ChengDMTapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) program. Drug Alcohol Depend. 2018;189:166–171.
45.
HuhnAS, HobelmannJG, StricklandJCDifferences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Netw Open. 2020;3(2):e1920843.
46.
MatusowH, DickmanSL, RichJDMedication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.
47.
SaundersE, MetcalfSA, WalshO,et al. “You can see those concentric rings going out”: Emergency personnel's experiences treating overdose and perspectives on policy-level responses to the opioid crisis in New Hampshire. Drug Alcohol Depend. 2019;204:107555.
48.
HoffmanKA, BakerR, KunkelLEBarriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Serv Res. 2019;19(1):862.
D'OnofrioG, O'ConnorPG, PantalonMVEmergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–1644.
51.
HindeJM, MarkTL, FullerL, DeyJ, HayesJ.Increasing access to opioid use disorder treatment: assessing state policies and the evidence behind them. J Stud Alcohol Drugs. 2019;80(6):693–697.
CanceJD, DoyleE.Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic. JAMA. 2020;324(23):2442–2444.
54.
GreenTC, BratbergJ, FinnellDS.Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.
